Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SmithKline Nicorette Mint Spurs Gum Sales 8% In Second Quarter

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham total smoking cessation sales increased 11% to $122 mil. in the second quarter, the firm reported July 20. The gain represents a slowdown, however, from first quarter growth of 68%.

You may also be interested in...



SB Nicorette Orange Ad Support Begins In November

SmithKline Beecham expects to introduce Nicorette Orange in drug stores, mass market outlets and supermarkets nationwide near the end of October.

SB Nicorette Orange Ad Support Begins In November

SmithKline Beecham expects to introduce Nicorette Orange in drug stores, mass market outlets and supermarkets nationwide near the end of October.

SB Nicorette Orange Ad Support Begins In November

SmithKline Beecham expects to introduce Nicorette Orange in drug stores, mass market outlets and supermarkets nationwide near the end of October.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS090118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel